PCSK9 and aortic stenosis: While PCSK9 inhibitors have already demonstrated cardiovascular event reduction and possibly reduce the incidence of aortic stenosis, RNA-based therapies offer a novel approach targeting the causal role of Lp(a) in these diseases.